On July 18, 2025, UBS analyst A.J. Rice reaffirmed a "Buy" rating for Elevance Health (ELV, Financial), underscoring a positive outlook for the company's stock despite modifying the price target. UBS has adjusted the price target to $435.00 from the previous $484.00, marking a decrease of 10.12%.
The decision to maintain the "Buy" rating indicates UBS's continued confidence in the potential performance of Elevance Health (ELV, Financial), even as the firm lowers its price expectations. The revised price target suggests cautious optimism, taking into account current market conditions and company-specific factors.
Investors and stakeholders may find this information significant, as UBS's analysis provides a directional insight into Elevance Health's (ELV, Financial) market positioning and potential growth trajectory moving forward.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 19 analysts, the average target price for Elevance Health Inc (ELV, Financial) is $439.91 with a high estimate of $556.33 and a low estimate of $310.00. The average target implies an upside of 56.70% from the current price of $280.73. More detailed estimate data can be found on the Elevance Health Inc (ELV) Forecast page.
Based on the consensus recommendation from 24 brokerage firms, Elevance Health Inc's (ELV, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Elevance Health Inc (ELV, Financial) in one year is $634.53, suggesting a upside of 126.03% from the current price of $280.73. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Elevance Health Inc (ELV) Summary page.
